Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0219 • ACR Convergence 2020
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Raquel Dos-Santos¹, Sytske Anne Bergstra², J. M. Maassen², Thomas Huizinga² and CF Allaart², ¹Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…
Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, NooRi Han⁹ and HoJae Lee⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…
Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Julia Dupont¹, Gregory Guernec², Yannick Degboé³, Frédéric Lioté⁴, Olivier Vittecoq⁵, Arnaud Constantin⁶ and Adeline Ruyssen Witrand⁷, ¹University Hospital of Thoulouse, Toulouse, ²Inserm UMR 1027, TOULOUSE CEDEX 9, France, ³University Hospital of Toulouse, Toulouse, ⁴AP-HP, Paris, France, ⁵University Hospital of Rouen, Rouen, France, ⁶Rheumatology Department, Toulouse University Hospital, Toulouse, France, ⁷Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Cesar Galan¹, Alan Puric², Guy Cozzi², Michele Hamburger³, Elisea Avalos-Reyes⁴ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Northbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
Abstract Number: 0745 • ACR Convergence 2020
Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment
Maya Breitman¹, Tracey Bonfield², Arnold Caplan³, Hillard Lazarus⁴, Maricela Haghiac⁵, Jane Reese⁶ and Nora Singer¹, ¹The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ²National Center of Regenerative Medicine Case Western Reserve University School of Medicine, Cleveland, OH, ³Skeletal Research Center Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Sero-positive rheumatoid arthritis (RA) is a chronic autoimmune disease that without effective treatment, leads to joint damage and disability. Not all patients respond to…
Abstract Number: 0762 • ACR Convergence 2020
Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
Marcos Lopez-Hoyos¹, Chelsea Bentow², Andy Ishii², Laura Martinez-Prat³ and Michael Mahler², ¹Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Research and Development, Inova Diagnostics, Barcelona, Spain
Background/Purpose: Over the past years, novel biomarkers have been identified in the sera of rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD)…
Abstract Number: 0779 • ACR Convergence 2020
Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Rheumatoid Arthritis
Sabrina Fechtner¹, Heather Berens², Elizabeth Bemis³, M Kristen Demoruelle², Carla J. Guthridge⁴, John Harley⁵, Judith James⁶, Jess Edison⁷, Kevin D. Deane⁸, Jill Norris⁹ and V. Michael Holers², ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, CO, ³Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁷Walter Reed National Military Medical Center, Bethesda, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Colorado School of Public Health, Aurora, CO
Background/Purpose: Viral infections, including infection with Epstein-Barr virus (EBV), have been suggested as environmental risk factors for rheumatoid arthritis (RA). EBV infections are known to…
Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Hayley Carr¹, Ilfita Sahbudin¹, Mark Maybury¹, Bernard Dyke², Jason Turner³, Nicola Gullick⁴, Karim Raza⁵, Dagmar Scheel-Toellner¹ and Andrew Filer¹, ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
Abstract Number: 0812 • ACR Convergence 2020
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Simon Helfgott¹, Janna Radtchenko², Nehad Soloman³, Kent Kwas Huston⁴, Jasvinder Singh⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁴Kansas City Physician Partners, Kansas City, MO, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Biologics have revolutionized the treatment of autoimmune diseases, though costs and payer restrictions have limited who are treated and when these agents are used. …
Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Hisashi Yamanaka¹, Mitsumasa Kishimoto², Kazuhisa Nakano³, Kenta Misaki⁴, Yuji Yamanishi⁵, Hiroaki Dobashi⁶, Masamitsu Natsumeda⁷, Toshiaki Miyamoto⁸, Koichi Amano⁹, Akira Sagawa¹⁰, Norihiko Koido¹¹, Corrona Japan Consortium¹², Leslie Harrold¹³, Tin-chi Lin¹³, Jeffrey Greenberg¹⁴ and Yoshiya Tanaka³, ¹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ²Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Kitaharima Medical Center, Ono, Japan, ⁵Hiroshima Rheumatology Clinic, Hiroshima, Japan, ⁶Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁷Mabi Memorial Hospital, Kurashiki, Japan, ⁸Seirei Hamamatsu General Hospital, Hamamatsu, Japan, ⁹Saitama Medical Center, Kawagoe, Japan, ¹⁰Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ¹¹Kawasaki RA & IM Clinic, Kawasaki, Japan, ¹²Corrona Japan Consortium, Japan, Japan, ¹³Corrona, LLC, Waltham, MA, ¹⁴Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
Abstract Number: 0973 • ACR Convergence 2020
Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis
Elisabetta Sciacca¹, Anna Surace², Myles Lewis¹, Salvatore Alaimo³, Vito Latora⁴, Felice Rivellese¹, Alfredo Pulvirenti³, Alfredo Ferro³ and Costantino Pitzalis⁵, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, Liverpool, United Kingdom, ³Bioinformatics Unit, Dept of Clinical and Experimental Medicine, University of Catania, Catania, Sicilia, Italy, ⁴School of Mathematical Sciences Queen Mary, University of London, London, United Kingdom, ⁵Queen Mary University of London, London, United Kingdom
Background/Purpose: Biomedical research uses many statistical/bioinformatics tools to find genes or proteins differentially expressed between patient group of interest. However, biological elements are related to…
Abstract Number: 1010 • ACR Convergence 2020
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Alyssa Dominique¹, Merete Hetland², Axel Finckh³, Jacques-Eric Gottenberg⁴, Florenzo Iannone⁵, Roberto Caporali⁶, Dan Nordstrom⁷, M Victoria Hernandez⁸, Carlos Sanchez-Piedra⁹, Fernando Sanchez-Alonso⁹, Karel Pavelka¹⁰, Zlatuše Křístková¹¹ and Teresa Simon¹², ¹Bristol-Myers Squibb Company, Princeton, NJ, ²The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ³Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵DETO-Rheumatology Unit, University of Bari, Bari, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Helsinki University Hospital and Helsinki University, Helsinki, Finland, ⁸Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹²Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ
Background/Purpose: Compared with the general population, patients with RA are at an increased risk of infection and certain malignancies, which may be increased further with…
Abstract Number: 1181 • ACR Convergence 2020
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Courtney O'Brien¹, Aman Kugasia², Anna Gorfin³, Lauren Klebek³, Joshlean Fair³ and Joel Block¹, ¹Rush University, Chicago, IL, ²Arthritis Clinic of Cypress and Katy, PA, Katy, TX, ³Rush University, Chicago
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…
Abstract Number: 1197 • ACR Convergence 2020
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Dawson Shaver¹, Daniel Van Kalsbeek¹, Ariadne Ebel¹, Daniel Hershberger¹, Cynthia Schmidt¹, Jill Poole¹, Geoffrey Thiele¹, Dana Ascherman², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is among the most frequent and severe extra-articular manifestations of RA, contributing significantly to the excess mortality among RA…
Abstract Number: 1213 • ACR Convergence 2020
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Jingyu Liu², Julie Zhu², Oscar Segurado³ and Daniel Furst*⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³SSI Strategy, San Jose, CA, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA
Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].